Lockie et al. () Level IV N=44 patients with known or suspected Exclusion criteria: Adenosine SP-CMR + LGE CAD UK A case series with either Contraindications for CMR or gadolinium-contrast agents; previous post-test or Mean age: 57 ± 10 years MI, CABG, ACS; impaired LVEF (<40%); and obstructive pulmonary outcomes n=9 women (21%) disease Previous PCI: 19% Low risk of bias (IHE 8/12) CAD risk factors: smoker 21% diabetes 19% family history 26% Ma et al. () Level IV N=50 consecutive patients with suspected Exclusion criteria: Adenosine SP-CMR + LGE CAD who were scheduled for primary China A case series with either Medical instability; known CAD; any contraindications to CMR (i.e. diagnostic ICA post-test or metallic implants such as pacemakers, defibrillators, cerebral outcomes Mean age: 56 ± 16 years aneurysm clips, ocular metallic deposits; severe claustrophobia); or n=22/50 women (44%) contraindications to adenosine (e.g., 2nd- or 3rd- degree AV block, Low risk of bias n=28/50 men (56%) history of asthma); and renal insufficiency (IHE 8/12) CAD risk factors: hypertension 36% hypercholesterolaemia 54% smoker 46% diabetes 18% family history 32% Merkle et al. () Level IV N=256 consecutive patients with known or Exclusion criteria: Adenosine SP-CMR suspected CAD and a time interval of less A case series with either Acute MI; previous CABG; severe claustrophobia; Germany than 4 weeks between CMR and ICA post-test or implants; a heart rate not well controlled; and outcomes n=32/73 women (44%) pulmonary disease requiring treatment with methyl xanthine Mean age: 63.4 ± 11.7 years derivatives. Low risk of bias (IHE 8/12) CAD risk factors: hypertension 78% hypercholesterolaemia 71% smoker 16%
Lockie et al. () UK Level IV A case series with either post-test or outcomes Low risk of bias (IHE 8/12) N=44 patients with known or suspected CAD Mean age: 57 ± 10 years n=9 women (21%) Previous PCI: 19% CAD risk factors: smoker 21% diabetes 19% family history 26% Exclusion criteria: Contraindications for CMR or gadolinium-contrast agents; previous MI, CABG, ACS; impaired LVEF (<40%); and obstructive pulmonary disease Adenosine SP-CMR + LGE Ma et al. () China Level IV A case series with either post-test or outcomes Low risk of bias (IHE 8/12) N=50 consecutive patients with suspected CAD who were scheduled for primary diagnostic ICA Mean age: 56 ± 16 years n=22/50 women (44%) n=28/50 men (56%) CAD risk factors: hypertension 36% hypercholesterolaemia 54% smoker 46% diabetes 18% family history 32% Exclusion criteria: Medical instability; known CAD; any contraindications to CMR (i.e. metallic implants such as pacemakers, defibrillators, cerebral aneurysm clips, ocular metallic deposits; severe claustrophobia); or contraindications to adenosine (e.g., 2nd- or 3rd- degree AV block, history of asthma); and renal insufficiency Adenosine SP-CMR + LGE Merkle et al. () Germany Level IV A case series with either post-test or outcomes Low risk of bias (IHE 8/12) N=256 consecutive patients with known or suspected CAD and a time interval of less than 4 weeks between CMR and ICA n=32/73 women (44%) Mean age: 63.4 ± 11.7 years CAD risk factors: hypertension 78% hypercholesterolaemia 71% smoker 16% Exclusion criteria: Acute MI; previous CABG; severe claustrophobia; implants; a heart rate not well controlled; and pulmonary disease requiring treatment with methyl xanthine derivatives. Adenosine SP-CMR
1237-AssessmentReport-Final.docx